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Summary Objectives The insulin-like growth factor (IGF)
signaling pathway has been implicated in the pathogenesis
of numerous tumor types, including non-small cell lung
cancer (NSCLC). Figitumumab is a fully human IgG2
monoclonal antibody against IGF-1 receptor (IGF-1R).
Methods This phase I, open-label, dose-escalation study
(ClinicalTrials.gov: NCT00603538) assessed the safety and
tolerability of figitumumab (6, 10 and 20 mg/kg) in
combination with carboplatin (area under the curve:
6 mg·min/mL) and paclitaxel (200 mg/m2) in Japanese
patients (N=19) with chemotherapy-naïve, advanced
NSCLC. Treatments were administered intravenously on
day 1 of a 21-day cycle for four to six cycles. Pharmaco-
kinetics, biomarkers, and antitumor activity were also
evaluated. Results Figitumumab in combination with
carboplatin and paclitaxel was well tolerated at doses up
to 20 mg/kg; no dose-limiting toxicities were observed at
this dose level. When given in combination, figitumumab
plasma exposure increased in an approximately dose-
proportional manner. The approximate 2-fold accumulation
following repeated administration supported the 21-day
regimen as appropriate for figitumumab administration.
Serum total IGF-1 and IGF binding protein-3 concentra-
tions increased following figitumumab dosing, but a clear
dose-dependent relationship was not demonstrated. Seven of
18 evaluable patients experienced a partial response. Con-
clusions Figitumumab 20 mg/kg in combination with
carboplatin and paclitaxel was well tolerated in
chemotherapy-naïve Japanese patients with NSCLC. Further
analysis of biomarker data is necessary for the development
of figitumumab therapy.
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Introduction
The insulin-like growth factor (IGF) signaling pathway
comprises IGF ligands (IGF-1 and IGF-2), IGF binding
proteins (IGFBP1–6) which regulate ligand bioavailability,
and IGF receptors (IGF-1R and IGF-2R) [1–3]. IGF
signaling has been implicated in the development of a
variety of tumors, including breast, colorectal, prostate, and
lung cancers [2, 3]. IGF-1R is a receptor tyrosine kinase
involved in the regulation of various biological processes,
including cell growth, proliferation, and inhibition of
apoptosis. In non-small cell lung cancer (NSCLC), IGF-
1R is frequently over-expressed in tumor tissue and also
mediates the proliferation of lung cancer cell lines [3–6].
Figitumumab (CP-751,871; Pfizer Inc, La Jolla, USA), a
fully human IgG2 monoclonal antibody (mAb) against
IGF-1R, is one of several agents currently in development
which target the IGF pathway [7]. Figitumumab mono-
therapy has been well tolerated in phase I studies of patients
with refractory solid tumors or multiple myeloma [8–12].
The safety and efficacy of figitumumab in combination
Y. Goto : I. Sekine :M. Tanioka : T. Shibata : C. Tanai :
H. Asahina :H. Nokihara :N. Yamamoto :H. Kunitoh :Y. Ohe :
T. Tamura (*)





H. Kikkawa : E. Ohki
Pfizer Oncology, Global Research and Development,
Tokyo, Japan
Invest New Drugs (2012) 30:1548–1556
DOI 10.1007/s10637-011-9715-4
with carboplatin and paclitaxel were investigated previously
in aWestern phase Ib/II study in patients with chemotherapy-
naïve, locally advanced or metastatic NSCLC [13]. Results
suggested that figitumumab in combination with chemo-
therapy was safe and effective in this patient population.
The aim of this phase I, open-label, dose-escalation
study was to assess the safety and tolerability of figitumu-
mab in combination with carboplatin and paclitaxel in
Japanese chemotherapy-naïve patients with advanced
NSCLC. Secondary objectives were to evaluate pharmaco-
kinetics, biomarkers, and antitumor activity.
Materials and methods
Study population
Patients eligible for inclusion in the study were aged 20–
74 years, had an Eastern Cooperative Oncology Group
(ECOG) performance status of 0 or 1 and had previously
untreated, measurable, stage IIIB/IV NSCLC. All patients had
adequate organ function assessed by hemoglobin (≥10 g/dL),
platelet (≥100 000 cells/μL), and absolute neutrophil (≥2,000
cells/μL) counts; serum creatinine (≤1.5 mg/dL), albumin
(≤3.0 g/dL), total bilirubin (≤1.8 mg/dL), and alanine amino-
tranferase and aspartate aminotransferase (≤80 IU/L) levels;
circulating glycosylated hemoglobin (HbA1c) <7% and
fasting plasma glucose levels <126 mg/dL.
Exclusion criteria included prior anticancer therapy for
advanced NSCLC, presence of symptomatic brain metasta-
ses or central nervous system metastases, history of active
malignancy other than NSCLC within the previous 5 years
(skin cancer other than malignant melanoma and in situ
cervical, gastric, and colorectal cancers were permitted),
treatment for pleural effusions and/or pericardial effusions,
gastrointestinal bleeding within the previous 3 months,
treatment with systemic corticosteroids within the previous
2 weeks, or neuropathy ≥grade 2 within the past 2 weeks.
Subjects with diabetes and significant cardiac disease,
including myocardial infarction, angina, uncompensated
congestive heart failure, and serious cardiac ventricular
arrhythmia, and uncontrolled hypertension within the past
6 months were also excluded.
The study protocol was approved by the Institutional
Review Board at the National Cancer Center, Tokyo, Japan,
and the study conformed to the provisions of the Declara-
tion of Helsinki (1996). All patients provided written,
informed consent.
Study design and dosing
This was a phase I, single-center, open-label, dose-escalation
study to evaluate the safety and tolerability of figitumumab in
combination with carboplatin (area under the curve [AUC]
6 mg·min/mL) and paclitaxel (200 mg/m2).
Treatments were administered intravenously on day 1 of
a 21-day cycle for four to six cycles, unless disease
progression or unacceptable toxicity was observed. Carbo-
platin was administered following completion of the
paclitaxel infusion, and figitumumab was administered
following completion of the carboplatin infusion. A
standard 3+3 dose-escalation scheme was used to escalate
the dose of figitumumab. The first cohort of patients
received figitumumab 6 mg/kg, and the second and third
cohorts received figitumumab at doses of 10 mg/kg and
20 mg/kg, respectively. To minimize the risk of hypersen-
sitivity, patients received prophylactic anti-allergy medica-
tion prior to paclitaxel administration, per the prescribing
information for paclitaxel. The 20 mg/kg dose was judged
effective and tolerable in phase I/II studies in Western
patients [8–11, 13] and therefore no dose-expansion cohort
was enrolled in this study.
Dose-limiting toxicities (DLTs) were figitumumab-
related grade 3 or 4 toxicities assessed during the first
treatment cycle according to National Cancer Institute
Common Terminology Criteria for Adverse Events (NCI
CTCAE) v3.0. DLTs included: grade 4 neutropenia lasting
≥7 days or complicated by fever (body temperature >38.0°C);
and grade 4 thrombocytopenia or grade ≥3 thrombocytopenia
necessitating a blood transfusion. Grade ≥3 non-hematologic
adverse events (AEs; including gastrointestinal events, hyper-
glycemia, and/or fatigue despite the use of adequate medical
intervention), and other clinically significant treatment-related
AEs identified by the investigator, were also considered as
DLTs.
Assessments and analyses
All patients who received at least one dose of figitumumab,
carboplatin or paclitaxel were assessed for safety. AEs were
graded according to the NCI CTCAE v3.0. Laboratory tests
were performed at regular intervals throughout the study
(including measurement of hematology, blood chemistry,
coagulation, and urinalysis parameters). Vital signs and
electrocardiograms (ECGs) were also assessed during
screening and at regular intervals throughout the study.
Blood samples for the measurement of circulating total
IGF-1 and IGFBP3 by radio-immunoassay were collected
prior to chemotherapy dosing and 168 h post-figitumumab
infusion in cycles 1–4, prior to dosing in cycles 5 and 6,
and at the end of the study. Circulating levels of human
growth hormone (hGH) and insulin (fasting) were assessed
at screening, day 1 (prior to dosing with study medication),
and day 22 of each cycle, and at the end of the study.
Glycosylated hemoglobin (HbA1c) levels were assessed at
screening only. Circulating glucose (fasting) and other
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blood chemistry parameters were assessed on days 8 and 15
of each cycle. Tumor assessments were performed at
baseline, during cycles 2, 4, and 6, and at end of study
treatment. Objective response was determined according to
Response Evaluation Criteria In Solid Tumors (RECIST
v1.0) [14].
Pharmacokinetic profiles of figitumumab were obtained
during cycles 1 and 4: blood samples were collected prior
to figitumumab infusion, and 1, 24, 72, and 168 h after
figitumumab infusion. In other cycles, samples were
collected prior to figitumumab infusion, and 1 h after
figitumumab infusion. An additional pharmacokinetic
blood sample was collected at the end of the study. Plasma
concentrations of figitumumab were determined by a
validated enzyme-linked immunosorbent assay. Briefly, an
IGF-1-soluble receptor was utilized to capture figitumu-
mab. Figitumumab bound to the receptor was detected
using a biotinylated mouse anti-human IgG2, followed by
Streptavidin–Horseradish Peroxidase conjugate, and visu-
alized using SureBlue™ peroxidase substrate. The lower
limit of quantitation for the assay was 120 ng/mL.
Pharmacokinetic parameters, which were calculated using
non-compartmental methods, included Cmax (maximum
observed plasma concentration after the end of figitumu-
mab infusion), AUC(0–day22) (area under the plasma
concentration–time curve from time zero to day 22 [the
nominal time of the pre-dose sample for the next cycle]),
AUCtau (AUC from time zero to tau [the actual time of the
pre-dose sample for the next cycle]), and t½ (apparent
disposition half-life). The accumulation ratio was calculated
as: cycle 4 AUCtau/cycle 1 AUCtau.
Due to the exploratory nature of this study, enrollment
was dependent upon the observed safety profile and
confirmatory inferential analyses were not planned.
Descriptive statistics were used to summarize patient
characteristics, safety, antitumor activity, and pharmaco-
kinetic parameters. Analyses of the relationships between
antitumor activity and circulating levels of total IGF-1,
IGFBP3, hGH, and insulin were conducted. Summary
statistical data are shown; statistical associations between
biomarker levels and clinical outcome were not investi-
gated due to the exploratory nature of these analyses and
the small patient numbers.
Results
Baseline characteristics
Nineteen patients were enrolled across three figitumumab
dose levels: 6 mg/kg, n=6; 10 mg/kg, n=7; 20 mg/kg, n=6.
All patients were Japanese, and demographic and baseline
characteristics are summarized in Table 1. Most patients
(n=15; 78.9%) presented with stage IV NSCLC. Fourteen
patients (73.7%) had adenocarcinoma, four patients
(21.1%) had squamous cell carcinoma, and one patient
had their histology classified as ‘NSCLC not otherwise
specified’.
Eighteen patients completed the first treatment cycle. One
patient in the 10-mg/kg cohort discontinued the study due to a
serious paclitaxel-related AE (hypersensitivity); this patient
did not receive figitumumab. Themedian number of treatment
cycles started for the 6-, 10-, and 20-mg/kg figitumumab dose
levels was 4 (range 2–6), 4 (range 1–6), and 4 (range 3–6),
respectively.
Safety and tolerability
DLTs were experienced by one patient at the figitumumab
6-mg/kg dose level (grade 4 thrombocytopenia) and by two
patients at the 10-mg/kg dose level (one patient had grade 4
hyperuricemia, grade 3 hypermagnesemia, grade 3 hypo-
natremia, and grade 3 hyperkalemia, and another patient
had grade 4 thrombocytopenia). No DLTs occurred in
Table 1 Patient characteristics at baseline
Characteristic Figitumumab dose levela
6 mg/kg 10 mg/kg 20 mg/kg
Enrolled patients, n 6 7 6
Median age (years) 54 40 63
Range 45–69 21–61 37–74
Gender, n
Male 3 4 5
Female 3 3 1
ECOG performance status, n
0 5 7 4
1 1 0 2
NSCLC histologic subtype, n
Adenocarcinoma 4 6 4
Squamous cell carcinoma 1 1 2
Not otherwise specified 1 0 0
Disease stage, n
IIIB 0 1 3
IV 6 6 3
Smoking history, n
Never smoker 4 3 0
Smoker 2 2 2
Ex-smoker 0 2 4
AUC area under the curve, ECOG Eastern Cooperative Oncology
Group, NSCLC non-small cell lung cancer
a Figitumumab in combination with carboplatin (AUC 6 mg·min/mL)
and paclitaxel (200 mg/m2 )
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patients treated at the highest figitumumab dose level of
20 mg/kg (Table 2).
The most common all-causality, non-hematologic AEs of
all grades across all dose levels and cycles were peripheral
sensory neuropathy (n=16 [84.2%]), anorexia (n=14
[73.7%]), and diarrhea (n=9 [47.4%]). Grade 3 and 4
treatment-related hematologic and non-hematologic AEs
occurring at each figitumumab dose level are presented in
Table 3. The only grade ≥3 non-hematologic AEs to occur
in two or more patients across all dose levels and cycles
were hyponatremia/blood sodium decrease (grade 3, n=3
[15.8%]), anorexia (grade 3, n=2 [10.5%]), and hyperuri-
cemia (grade 4, n=2 [10.5%]); hyperuricemia was the only
grade 4 non-hematologic AE reported. There were no cases
of grade 3 or 4 hypoglycemia or hyperglycemia. Most
grade 3 or 4 non-hematologic AEs were observed during
cycle 1, and figitumumab dose level did not appear to
influence the frequency of grade 3 or 4 AEs.
Grade 3 treatment-related hematologic AEs (across all
dose levels and cycles) were neutropenia (n=5 [26.3%]),
leukopenia (n=4 [21.1%]), anemia (n=2 [10.5%]), and
thrombocytopenia (n=1 [5.3%]), and grade 4 treatment-
related hematologic AEs were neutropenia (n=11 [57.9%])
and thrombocytopenia (n=3 [15.8%]; Table 3). No
treatment-related deaths occurred at any figitumumab dose
level.
Pharmacokinetics
When given in combination with carboplatin and paclitaxel,
plasma concentrations of figitumumab declined in a multi-
exponential manner (Fig. 1a, b). Both Cmax and AUC
within the first cycle increased in an approximately dose-
proportional manner (Table 4). As indicated by the
accumulation ratio, repeated administration of figitumumab
every 21 days resulted in moderate accumulation (an
approximate 2-fold increase in plasma exposure in the
limited number of patients with sufficient data in cycle 4;
Table 4). The t½ of figitumumab was at least 248 h (more
than 10 days) for all three dose levels, and achieved the t½
of endogenous IgG2 (approximately 21 days) in some
patients.
Biomarkers
Serum total IGFBP3, IGF-1 and hGH concentrations
increased following figitumumab dosing compared with
baseline values for each dose level (Fig. 2a–c). However, a
clear dose-dependent relationship was not demonstrated,
and the levels of insulin levels were not changed clearly
prior and after figitumumab administration (data not
shown).
Antitumor activity
Of 18 evaluable patients, seven experienced a partial
response (PR; 38.9%). One PR was observed at the
figitumumab 6-mg/kg dose level, and three PRs were
observed at each of the 10- and 20-mg/kg dose levels.
PRs were observed in patients with adenocarcinoma (five
of 14 patients [35.7%]) and in patients with squamous cell
carcinoma (two of four patients [50.0%]). No patient had a
complete response. Stable disease (SD) was observed in
eight patients (44.4%; three at each of the 6- and 20-mg/kg
dose levels, and two at the 10-mg/kg dose level), and
progressive disease (PD) was observed in two patients
(11.1%; both at the 6-mg/kg dose level).
Relationship between antitumor activity and biomarkers
Serum total IGFBP3 and IGF-1 concentration–time profiles
were stratified by best response (PR, SD, and PD,
respectively) to evaluate the relationship between concen-
trations of biomarkers and clinical response. No clear








1 6 mg/kg 200 6 6 Grade 4 thrombocytopenia (n=1)
2 10 mg/kg 200 6 7 Grade 3: hyperkalemia, hypermagnesemia, hyponatremia; grade 4
hyperuricemia (n=1) Grade 4 thrombocytopenia (n=1)
3 20 mg/kgb 200 6 6 None
DLT dose-limiting toxicity
a If none of the three patients in the 6 mg/kg cohort experienced a DLT during cycle 1, subjects were enrolled onto the next dose level. If one DLT
was observed, the cohort was to be expanded to six patients. If none of the three or two or less of the six patients experienced a DLT, then dose
escalation was to be continued and three patients were enrolled to the 10 mg/kg cohort. In a similar manner depending on observed DLTs, the
10 mg/kg cohort could be expanded to six patients and dose escalation continued to a 20 mg/kg cohort of six patients. If two or more of the three,
or three or more of the six patients experienced a DLT, dose escalation would be stopped
b Six patients dosed, and 20 mg/kg deemed tolerable if two or fewer of the six patients experienced a DLT
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differences were observed in the IGFBP3 concentration–
time profiles according to clinical response, or when
baseline IGFBP3 concentration was stratified by best
response (Fig. 3a, b). However, the serum total IGF-1
concentration–time profile in patients with PR as their best
response was higher than the profiles in both SD and PD
patients (Fig. 3c). Higher baseline serum total IGF-1
concentrations were also observed for patients with PR
compared with patients with SD/PD as best response
(Fig. 3d).
Discussion
Figitumumab in combination with carboplatin and pacli-
taxel was well tolerated at doses up to 20 mg/kg in
chemotherapy-naïve Japanese patients with advanced
NSCLC in this phase I study. No DLTs were observed at
the highest figitumumab dose level of 20 mg/kg. In
addition, no grade 3 or 4 AEs appeared to show dose
dependency, and there was no apparent tendency towards
cumulative toxicity.
Table 3 Treatment-related AEs with maximum CTC grade ≥3, in cycle 1 and all cycles. The numbers of patients are shown for grades 3 and 4
AEs separately, and for all grades
Figitumumab dose level
6 mg/kg (n=6) 10 mg/kg (n=7) 20 mg/kg (n=6)
Cycle 1 All cycles Cycle 1 All cycles Cycle 1 All cycles
All G3 G4 All G3 G4 All G3 G4 All G3 G4 All G3 G4 All G3 G4
AEs, hematologic
Anemia 4 0 0 5 0 0 3 0 0 3 1 0 4 0 0 5 1 0
Leukopenia 6 0 0 6 1 0 6 1 0 6 1 0 5 0 0 6 2 0
Neutropenia 6 2a 3 6 0 5 6 1 2 6 3 2 5 2 1 6 2 4
Thrombocytopenia 4 0 1 5 0 1 5 0 1 5 0 1 4 1 0 6 1 1
AEs, non-hematologic
Anorexia 2 1 0 3 2 0 5 0 0 6 0 0 5 0 0 5 0 0
Diarrhea 3 0 0 3 0 0 1 0 0 2 1 0 3 0 0 4 0 0
Hyperkalemia 0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0
Hypermagnesemia 0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0
Hypersensitivity 0 0 0 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0
Hyperuricemia 0 0 0 0 0 0 2 0 1 2 0 1 2 0 1 2 0 1
Hyponatremia 2 1 0 2 1 0 1 1 0 1 1 0 1 0 0 3 1 0
Peripheral sensory
neuropathy
3 0 0 5 0 0 4 0 0 5 0 0 2 0 0 6 1 0
Vomiting 1 0 0 2 1 0 2 0 0 2 0 0 1 0 0 1 0 0
AE adverse event, All all grades, CTC Common Terminology Criteria, G grade
a Two patients with grade 3 neutropenia during cycle 1 experienced worsening of symptoms to grade 4 after cycle 2
Fig. 1 Concentration–time pro-
files of plasma figitumumab.
Data shown are mean + standard
deviation
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No cases of grade 3 or 4 hyperglycemia (treatment-
related or all-causality) were reported in the present study
(grade 2 hyperglycemia was reported in one patient).
Hyperglycemia has been reported in other studies of
figitumumab and in studies of other IGF-1R-targeted mAbs
[8–11, 13, 15–17]. Hyperglycemia may be a characteristic
of the anti-IGF-1R class of compounds; however, its
mechanism is unknown.
Incidences of grade 3 and 4 treatment-related neutropenia
and thrombocytopenia in the figitumumab arm of the larger
Western phase II randomized study of figitumumab in
combination with paclitaxel and carboplatin in chemotherapy-
naïve NSCLC were 28% and 7%, respectively, compared with
84% and 21% in the current trial [13]. Similar ethnic
differences in the incidence of neutropenia have also been
observed in a Japanese–US common-arm analysis of carbo-
platin plus paclitaxel in advanced NSCLC, and were
suggested to be related to differences in allelic distribution
of genes associated with DNA repair and paclitaxel disposi-
tion [18]. However, such an ethnic difference was not
observed for thrombocytopenia [18]. Further studies would
be required to determine whether there are pharmacogenetic
or other reasons for ethnic differences in the incidence of
thrombocytopenia in patients treated with figitumumab.
In line with previous phase I studies [8–11], figitumumab
plasma exposure increased in an approximately dose-
proportional manner and concentrations declined in a
multi-exponential manner when figitumumab 6–20 mg/kg
was given in combination with carboplatin and paclitaxel in
the present study. The approximate 2-fold accumulation
following repeated administration supported the 21-day
regimen as appropriate for figitumumab administration in
Japanese patients; similar accumulation was reported in
Western studies [8–11]. No relationship between ethnicity
and pharmacokinetics was expected, since figitumumab (as a
mAb) extravasates mainly by convection and is eliminated
by catabolism and/or target-mediated clearance.
High serum total IGF-1 and low IGFBP3 levels have
been associated with higher incidence of NSCLC [19].
Hepatic IGF-1 production is stimulated by hGH, and hGH
production is regulated by IGF-1 through negative feedback
[20]. A previous phase I study demonstrated that single-
agent figitumumab (20 mg/kg) altered the endocrine
feedback mechanisms regulating hGH [8]. In the present
study, both hGH and serum total IGF-1 concentrations
appeared to increase following dosing with study medica-
tion, and this suggests blockade of IGF-1R with loss of
IGF-1 regulatory feedback at the pituitary. In a phase I
Table 4 Plasma pharmacokinetic parameters (mean ± SD) of figitumumab given in combination with carboplatin and paclitaxel









6 6 113±16 22,400±4,050 264a 4 178±35 39,000, 66,000b 1.7, 2.6b
10 6 197±33 36,700±10,400 301a 4 294±61 96,100, 96,800b 2.2, 2.2b
20 6 485±59 82,700±11,200 248a 5 550±89 116,000, 190,000b 1.6, 2.1b
AUC(0–day22) area under the plasma concentration–time curve from time zero to day 22, AUCtau AUC from time zero to tau (the actual time of the
pre-dose sample for the next cycle), Cmax maximum observed plasma concentration after the end of figitumumab infusion, SD standard deviation,
t1/2 apparent disposition half-life
a n=4 at 6 mg/kg, n=1 at 10 mg/kg, and n=4 at 20 mg/kg (sampling was not sufficient to capture terminal disposition phase in other patients)
b n=2
Fig. 2 Circulating biomarker concentrations during study treatment: concentration–time profile of serum IGFBP3 (panel a), serum total IGF-1
(panel b), and serum hGH (panel c). Data shown are mean ± standard deviation (panel a and panel b) and mean + standard deviation (panel c)
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study in myeloma patients and in the Western phase II trial
in NSCLC patients described above, dose-dependent
sustained elevations of serum IGF-1 and IGFBP3 concen-
trations were observed following administration of figitu-
mumab [10, 21], indicating dose-dependent blockade of
IGF-1R by figitumumab. However, a similar dose-
dependent relationship between figitumumab and circulat-
ing IGF-1 and IGFBP3 concentrations was not clearly
demonstrated in the current phase I study. Large inter-
individual variability in serum total IGF-1 and IGFBP3
concentrations is known to occur naturally, and the differ-
ences between the studies may reflect the small number of
patients included in each dose cohort level in the current
study. Alternatively, the lack of a dose-dependent elevation
of IGF-1 noted in this study may be related to the Japanese
patients in this study having lower body mass index (BMI)
compared with patients in other figitumumab studies. This
possibility is supported by a report which suggests a
relationship between BMI and IGF-1 levels [22].
Closure of the phase III studies of figitumumab in
NSCLC (ADVIGO [ADVancing IGF-IR in Oncology] 1016
and 1018) due to potential futility of the combination
regimens (figitumumab with paclitaxel plus carboplatin,
and with erlotinib, respectively) has underscored the need
to identify patients most likely to benefit from anti-IGF-1R
therapy [23]. Studies have indicated that baseline levels of
circulating free IGF-1 may be a positive biomarker for
clinical response to figitumumab [13, 21, 23]. In the present
study, serum total IGFBP3 and IGF-1 concentration–time
profiles were stratified by best response as part of an
exploratory analysis of the relationship between biomarker
levels and antitumor activity. No clear differences were
observed in the IGFBP3 concentration–time profiles
according to clinical response, or when baseline IGFBP3
concentration was stratified by best response. However, the
serum total IGF-1 concentration–time profile in patients
with PR as their best response was higher than the profiles
in both SD and PD patients. Additionally, baseline serum
total IGF-1 concentration appeared higher in patients with
PR compared with patients having SD/PD as their best
response. Although the relationship between outcome and
biomarkers was not examined statistically due to the
exploratory nature of these investigations and the small
number of patients, these observations suggest that serum
Fig. 3 Relationship between
biomarkers and clinical re-
sponse: serum IGFBP3 concen-
tration–time profiles by best
response (panel a); baseline se-
rum IGFBP3 concentrations by
best response—boxes represent
median, 25%, and 75% percen-
tiles (panel b); serum total IGF-
1 concentration–time profiles by
best response (panel c); baseline
serum total IGF-1 concentra-
tions by best response—boxes
represent median, 25%, and
75% percentiles (panel d). Pts
patients
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total IGF-1 concentrations prior to the start of treatment
may also be a positive biomarker for response.
In summary, figitumumab 20 mg/kg in combination with
carboplatin and paclitaxel was well tolerated in chemotherapy-
naïve Japanese patients with advanced NSCLC. Serum total
IGF-1 is a potential biomarker for clinical response to
figitumumab and requires further investigation.
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